Here begins the text.

Notifications Related to Safety Measures (Drugs)

Notification

Date Title Original in Japanese
September 1, 2020
Administrative Notice
Results of the Health Effect Assessment of the Use of Ranitidine Hydrochloride Products or Nizatidine Products in Which N-dimethylnitrosamine Was Detected
Reference material : Risk assessment of the use of ranitidine products and nizatidine products in which carcinogenic substance N-nitrosodimethylamine was detected
PDF
May 27, 2020
PSEHB/GAD0527 No.1
PSEHB/PED0527 No.5
PSEHB/PSD0527 No.1
PSEHB/CND0527 No.1
Extension of the Period for Transitional Measures on Methylphenidate Hydrochloride Preparations (Concerta Tablets 18 mg, 27 mg, 36 mg) due to the Covid-19 PDF
May 7, 2020
PSEHB/PED 0507 No.12
PSEHB/PSD 0507 No.1
Points for Consideration concerning the Use of Remdesivir PDF
March 25, 2020
PSEHB/PED 0325 No.1
PSEHB/PSD 0325 No.1
Points for Consideration concerning the Use of Trastuzumab Deruxtecan (genetical recombination) PDF
February 28, 2020
PSEHB/PSD 0228 No.5
Revisions of Precautions in Package Inserts concerning the Dosing Intervals between Different Vaccines PDF
February 25, 2020
HSB/HSD 0225 No.3
PSEHB/PSD 0225 No.8
PSEHB/CND 0225 No.5
Resolution of the Delayed Supply of  Haemophilus influenzae type b Conjugate Vaccine (conjugate to tetanus toxoide) (branded name ActHIB) PDF
February 21, 2020
PSEHB/GAD0221 No.1
PSEHB/PED0221 No.5
PSEHB/PSD0221 No.1
PSEHB/CND0221 No.1
Points for Consideration concerning the Use of Modafinil (MODIODAL Tablets 100mg)
(Appendix) Summary of the Guidance of Appropriate Medication for MODIODAL Tablets
PDF
PDF
January 27, 2020
HSB/HSD 0127 No.2
PSEHB/PSD 0127 No.2
PSEHB/CND 0127 No.4
Measures concerning the Temporarily Delayed Supply of Haemophilus influenzae type b Conjugate Vaccine (Conjugate to Tetanus Toxoid) (branded name: ActHIB) PDF
December 26, 2019
Administrative Notice
Handling of Solvent Containers Bundled with Haemophilus influenzae type b Conjugate Vaccine (Conjugate to Tetanus Toxoid) (branded name: ActHIB) (points to be considered) PDF
December 9, 2019
Administrative Notice
Measures for the Detection of Carcinogenic Substances from Metformin Hydrochloride PDF
December 6, 2019
PSEHB/PED1206 No.5
Points to be Considered concerning the Use of Panobinostat Lactate Preparations PDF
December 6, 2019
PSEHB/PED1206 No.1
PSEHB/PSD1206 No.1
Points to be Considered concerning the Use of Crizotinib Preparations PDF
November 21, 2019
Administrative Notice
Issuance of Briefing Material for Package Inserts of Generic Prescription Drugs (information provision) PDF
November 21, 2019
PSEHB/PSD1121 No.2
Efforts to Raise Awareness of Precautions regarding Anti-Influenza Drugs PDF
September 17, 2019
Administrative Notice
Measures for the Detection of Carcinogenic Substances from Ranitidine Hydrochloride PDF
September 4, 2019
PSEHB/GAD0904 No.1
PSEHB/PED0904 No.3
PSEHB/PSD0904 No.1
PSEHB/CND0904 No.1
Points for Consideration concerning the Use of Methylphenidate Hydrochloride Preparations (Concerta Tablets 18 mg, 27 mg, 36 mg)
(Appendix) Outline of Logistic Management Implemented by Marketing Authorization Holder
PDF
PDF
July 30, 2019
PSEHB/PED0730 No.5
PSEHB/PSD0730 No.5
Points for Consideration concerning the Use of Erlotinib Hydrochloride Preparations Indicated for Non-small Cell Lung Cancer (NSCLC) and Unresectable Pancreatic Cancer PDF
July 30, 2019
PSEHB/PED0730 No.1
PSEHB/PSD0730 No.4
Points for Consideration concerning the Use of Everlorimus Preparations Indicated for Renal Cell Carcinoma and Neuroendocrine Tumour PDF
July 9, 2019
PSEHB/PSD0709 No.11
PSEHB/PSD0709 No.12
Dissemination of Information concerning the Revisions of Precautions for Medicines Containing Codeine Phosphate Hydrate, Dihydrocodeine Phosphate, or Tramadol Hydrochloride (request) PDF
July 9, 2019
PSEHB/PED0709 No.9
PSEHB/PSD0709 No.13
Partial Revision of Precautions Included in Package Inserts, etc. of Cold Medicines, etc.
(Appendix: Precautions included in Package Inserts, etc. for Cold Medicines, etc.)
PDF
PDF
July 9, 2019
PSEHB/PED0709 No.5
PSEHB/PSD0709 No.1
Points for Consideration concerning the Use of Erlotinib Hydrochloride Preparations Indicated for Non-small Cell Lung Cancer (NSCLC) and Unresectable Pancreatic Cancer
*Abolished on July 30, 2019
PDF
July 9, 2019
PSEHB/PED0709 No.1
PSEHB/PSD0709 No.2
Points for Consideration concerning the Use of Everlorimus Preparations Indicated for Renal Cell Carcinoma and Neuroendocrine Tumour
*Abolished on July 30, 2019
PDF
Jun 18, 2019
PSEHB/PED0618 No.9
Points for Consideration concerning the Use of Ravulizumab (genetical recombination) Preparations PDF
June 18, 2019
PSEHB/PSD0618 No.2
Revisions of Precautions in Package Inserts concerning "glaucoma" etc. as a contraindication for anticholinergic drugs PDF
June 14, 2019
HPB/GAD/MSPO0614 No.1
PSEHB/PSD0614 No.1
Guidance of Appropriate Medication for Elderly Patients  [particular (by recuperation environment)] PDF
May 30, 2019
PSEHB/PED0530 No.11
PSEHB/PSD0530 No.2
Partial Revision of Precautions included in Package Inserts, etc. for Cold Medicines, etc. PDF
March 26, 2019
PSEHB/GAD0326 No.1
PSEHB/PED0326 No.1
PSEHB/PSD0326 No.8
PSEHB/CND0326 No.50
Points for Consideration concerning the Use of Lisdexamfetamine Mesilate Preparations
(Appendix) Outline of Proper Logistic Management of Vyvanse Capsules
PDF
PDF
March 26, 2019
PSEHB/PSD0326 No.1
Direct Patient Reporting of Adverse Drug Reactions
(Appendix) Plan and Procedures for Implementation
(Attachment) Reporting Form
PDF
PDF
PDF
March 15, 2019
Administrative Notice
Issuance of Briefing Material for Instructions for Package Inserts of Prescription Drugs (information provision)
Reference 1: Instructions for Package Inserts of Prescription Drugs (PSEHB Notification NO. 0608-1 by Director-General Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare dated June 8, 2017)
Reference 2: Instructions for Package Inserts of Vaccines (PSEHB Notification NO. 1227 by Director-General Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare dated December 27, 2017
PDF
PDF
PDF
February 28, 2019
PSEHB/PSD0228 No.1
PSEHB/PSD0228 No.2
Results of the Interim Report on the Use Results Surveys of Osimertinib Mesilate Preparations (request for circulation) PDF
PDF
PDF
January 29, 2019
HPB/GAD0129 No.2
HPB/EAD0129 No.1
PSEHB/GAD0129 No.2
PSEHB/CND0129 No.1
Efforts to Ensure Identification etc. of Pharmaceuticals PDF
November 26, 2018
PSEHB/PSD1126 No.2
Efforts to Raise Awareness of Precautions regarding Anti-Influenza Drugs PDF
November 14, 2018
Administrative Notice
Handling of Freeze-dried BCG Vaccines (for percutaneous use; for single dose) (points for consideration) PDF
November 9, 2018
PSEHB/PED1109 No.6
PSEHB/PSD1109 No.4
PSEHB/CND1109 No.1
Establishment of Management Indicators for Carcinogenic Substances contained in Angiotensin II-receptor Antagonists (request) PDF
November 8, 2018
Administrative Notice
Quality of Diluent for Reconstitution of Freeze-dried BCG Vaccines (for percutaneous use; for single dose) PDF
October 5, 2018
Administrative Notice
Results of Deliberation of the FY 2018 Subcommittee on Drug Safety of the Committee on Drug Safety (the 8th meeting) on the Detection of Carcinogenic Substances from Valsartan Preparations PDF
May 29, 2018
HPB/GAD/MSPO 0529 No.1
PSEHB/PSD0529 No.1
Guidance concerning Appropriate Use of Medication by Elderly Patients (general) PDF
May 25, 2018
PSEHB/PED0525 No.3
PSEHB/PSD0525 No.1
Points for Consideration concerning the Use of Tofacitinib Citrate Preparations PDF
April 13, 2018
PSEHB0413 No.4
Self-inspections of Pharmaceuticals, etc. Manufactured from Materials, etc. Derived from Species of the Finnish Cervidae Family PDF
March 29, 2018
PSEHB/PED0329 No.17
PSEHB/PSD0329 No.1
Precautions Included in Package Inserts, etc. of OTC Crude Drug Products PDF
March 27, 2018
PSEHB/PSD0327 No.1
Revisions of Precautions for Antimicrobials PDF
February 1, 2018
PSEHB/PSD0201 No.1
PSEHB/BBPD0201 No.1
Dissemination of Safety Measures Applicable when Using Blood Products for Transfusion PDF
January 24, 2018
PSEHB/PSD0124 No.1
PSEHB/PSD0124 No.2
Results of the Interim Report on the Use Results Surveys of Osimertinib Mesilate Preparations (request for circulation) PDF
PDF
PDF
January 19, 2018
PSEHB/PED0119 No.1
PSEHB/PSD0119 No.1
Points for Consideration concerning the Use of Inotuzumab Ozogamicin (genetical recombination) Preparations PDF
January 16, 2018
PSEHB/PED0116 No.1
PSEHB/PSD0116 No.1
Correction of the "Partial Revision of Precautions Included in Package Inserts, etc. for Cold Medicines, etc."
(Appendix: Precautions included in Package Inserts, etc. for Cold Medicines, etc.)
PDF
PDF
December 25, 2017
PSEHB/PED1225 No.5
PSEHB/PSD1225 No.1
Points for Consideration concerning the Use of Olanzapine Preparations PDF
December 25, 2017
PSEHB/PED1225 No.1
Points for Consideration concerning the Use of Eculizumab (genetical recombination) Preparations PDF
December 4, 2017
PSEHB/PSD1204 No.2
PSEHB/BBPD 1204 No.1
Dissemination of Safety Measures concerning the Use of Concentrated Human Platelet Preparations PDF
November 28, 2017
PSEHB/PSD1128 No.2
PSEHB/PSD1128 No.3
Dissemination of Information concerning the Revisions of Precautions for Gadolinium-based Contrast Agents (request) PDF
November 27, 2017
PSEHB/PSD1127 No.8
Efforts to Raise Awareness of the Precautions for Anti-Influenza Drugs PDF
October 17, 2017
PSEHB/PED1017 No.2
PSEHB/PSD1017 No.3
Partial Revision of Precautions Included in Package Inserts, etc. for Cold Medicines, etc.
 (Appendix: Precautions included in Package Inserts, etc. for Cold Medicines, etc.) * Abolished on Jan. 16, 2018
PDF
PDF
September 27, 2017
PSEHB/PED0927 No.11
Request for Cooperation in Post-marketing Surveillance and Proper Use of Glecaprevir Hydrate/Pibrentasvir Preparations PDF
September 27, 2017
PSEHB/PED0927 No.7
Points for Consideration concerning the Use of Cedar Pollen Extract Tablets for Sublingual Administration PDF
September 27, 2017
PSEHB/PED0927 No.4
PSEHB/PSD0927 No.1
Points for Consideration concerning the Use of Bezlotoxumab (genetical recombination) PDF
July 4, 2017
PSEHB/SD0704 No.2
PSEHB/SD0704 No.3
Dissemination of Information concerning the Revisions of Precautions for Medicines Containing Codeine Phosphate or Dihydrocodeine Phosphate (request) PDF
July 4, 2017
PSEHB/SD0704 No.8
PSEHB/PED0704 No.5
Partial Revision of Precautions Included in Package Inserts, etc. of Cold Medicines, etc.
(Appendix: Precautions included in Package Inserts, etc. for Cold Medicines, etc.)
* Abolished on Oct. 17, 2017
PDF
PDF
July 3, 2017
PSEHB/PED0703 No.4
PSEHB/SD0703 No.1
Points for Consideration concerning the Use of Quetiapine Fumarate Extended Release Preparations PDF
March 30, 2017
PSEHB/PED0330 No.1
Points for Consideration concerning the Use of Forodesine Hydrochloride Preparations PDF
March 21, 2017
PSEHB/SD0321 No.2
PSEHB/SD0321 No.3
Dissemination of Information concerning the Revisions of Precautions for Hypnotic-sedatives, Anxiolytics, and Antiepileptics (request) PDF
November 25, 2016
PSEHB/SD1125 No.2
Dissemination of Information concerning the Revisions of Precautions for Milnacipran Hydrochloride, Duloxetine Hydrochloride, and Venlafaxine Hydrochloride (request) PDF
November 22, 2016
PSEHB/SD1122 No.2
PSEHB/SD1122 No.3
Dissemination of Information concerning the Revisions of Precautions for Polaprezinc (request) PDF
November 18, 2016
PSEHB/SD1118 No.8
Efforts to Raise Awareness of the Precautions for Anti-Influenza Drugs PDF
October 24, 2016
PSEHB/SD1024 No.1
PSEHB/SD1024 No.2
PSEHB/SD1024 No.3
Dissemination of Information concerning Fulminant Type 1 Diabetes when Using Pembrolizumab (genetical recombination) Preparations PDF
October 18, 2016
PSEHB/SD1018 No.4
Dissemination of Information concerning the Revisions of Precautions for Warfarin Potassium and Azole Antifungal Agents (oral and injectable dosage forms) (request) PDF
October 18, 2016
Administrative notice
Revisions of Precautions for Preparations Containing Pioglitazone Hydrochloride PDF
September 28, 2016
PSEHB/PED0928 No.1
Points for Consideration concerning the Use of Ponatinib Hydrochloride Preparations PDF
July 22, 2016
PSEHB/SD0722 No.3
PSEHB/SD0722 No.4
Precautions concerning Interstitial Lung Disease when Administering Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (request) PDF
May 31, 2016
PSEHB/SD0531 No.3
Revisions of Precautions PDF
May 31, 2016
PSEHB/SD0531 No.2
Revisions of Precautions for Local Antimicrobial Agents Containing Chlorhexidine Gluconate PDF
May 19, 2016
PSEHB/PED0519 No.1
PSEHB/SD0519 No.1
Dissemination of Information concerning Safety Management on Teratogenicity of Mycophenolate Mofetil Preparations PDF
April 21, 2016
Administrative Notice
Revisions of Precautions for OTC Drugs Containing Pseudoephedrine Hydrochloride or Pseudoephedrine Sulfate PDF
January 28, 2016
PSEHB/SD0128 No.1
PSEHB/SD0128 No.2
PSEHB/SD0128 No.3
Dissemination of Information concerning Fulminant Type 1 Diabetes when Using Nivolumab (genetical recombination) Preparations (request) PDF
October 13, 2015
PSEHB/SD1013 No.1
Revision of the Package Insert for Injections Containing Benzyl Alcohol as an Excipient PDF
April 23, 2015
Administrative Notice
Q&A concerning Precautions Included in Package Inserts etc. of Cold Medicines etc. PDF
April 6, 2015
Administrative Notice
Revisions of Precautions PDF
April 1, 2015
PFSB/SD0401 No.2
PFSB/ELD0401 No.9
Partial Revision of Precautions Included in Package Inserts, etc. of Cold Medicines etc.
(Appendix: Precautions included in Package Inserts, etc. for Cold Medicines, etc.) * Abolished on July 4, 2017
PDF
PDF
January 22, 2015
Administrative Notice
Concerning Changes to the Content of Revisions of Precautions PDF
October 21, 2014
PFSB/SD1021 No.1
Revisions of Precautions for Acetaminophen (prescription drugs) PDF
December 2, 2013
PFSB/SD1202 No.2
Compliance with the Ministerial Ordinance on Good Vigilance Practices for Marketing Authorization Holders (MAHs) (to relevant organizations such as the Federation of Pharmaceutical Manufacturers' Associations of Japan [FPMAJ]) PDF
December 2, 2013
PFSB/SD1202 No.1
Compliance with the Ministerial Ordinance on Good Vigilance Practices for Marketing Authorization Holders (MAHs) (to prefectural governors) PDF
August 6, 2013
Administrative Notice
Revisions of Precautions for OTC Drugs Containing Pseudoephedrine Hydrochloride or Pseudoephedrine Sulfate PDF
March 26, 2013
Administrative Notice
Co-administration of Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors) or Angiotensin II Receptor Blockers (ARB) with Aliskiren Fumarate PDF
March 11, 2013
PFSB 0311 No.7
Enforcement of the Ministerial Ordinance on Partial Revision of Ministerial Ordinance on Good Vigilance Practice (GVP) for Drugs, Quasi-drugs, Cosmetics, and Medical Devices, and Ministerial Ordinance on Good Post-marketing Study Practice (GPSP) for Drugs PDF
January 25, 2013
Administrative Notice
Language related to Renal Impairment in the Precautions for OTC Drugs (Response) PDF
December. 11, 2012
PFSB 1211 No.8
Self-inspection of Pharmaceuticals and Medical Devices, etc. Manufactured using Materials Derived from Bovine Specimens, etc. Originating from Brazil PDF
June 6, 2012
Administrative Notice
Additional Ingredient Labeling Requirements for Drugs, Quasi-drugs, and Cosmetics Containing Cochineal-derived Substances, etc. PDF
May 11, 2012
PFSB/ELD0511 No.5
PFSB/SD0511 No.3
PFSB/CND0511 No.2
Medicated Gelatin, etc. Containing Chromium Exceeding the Maximum Safe Level Standard in China (Attention: Commissioners of Prefectural Health Supervising Departments, Commissioners of Prefectural/Municipal/Special Ward Health Departments (Bureaus)
Reference: (Chairmen of the Federation of Pharmaceutical Manufacturers' Associations of JAPAN,  Japan Pharmaceutical Manufacturers Association (JPMA), Japan Bulk Pharmaceutical Manufacturers Association, The Pharmaceutical Research and Manufacturers of America (PhRMA) Japan-based Executive Committee (JBEC), American Chamber of Commerce in Japan (ACCJ) Pharmaceuticals Subcommittee, European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, Japan Cosmetic Industry Association (JCIA), The Japan Federation of Medical Devices Associations (JFMDA), American Medical Devices and Diagnostics Manufacturers' Association (AMDD), and the European Business Council in Japan Medical Equipment & Diagnostics Committee)
PDF
PDF
May 11, 2012
PFSB/ELD0511 No.1
PFSB/SD0511 No.1
Ingredient Labeling Requirements for Drugs, Quasi-drugs, and Cosmetics Containing Cochineal-derived Substances, etc. PDF
April 19, 2012
PFSB/ELD0419 No.18
PFSB/SD0419 No.4
PFSB/CND0419 No.1
Quality and Safety Assurance of Pharmaceuticals etc. using Gelatin Capsules (Attention to: Commissioners of Prefectural Health Supervising Departments, Commissioners of Cities with Public Health Centers and Special Wards)
Reference (Chairmen of the Federation of Pharmaceutical Manufacturers' Associations of JAPAN,  Japan Pharmaceutical Manufacturers Association (JPMA), Japan Bulk Pharmaceutical Manufacturers Association, The Pharmaceutical Research and Manufacturers of America (PhRMA) Japan Based Executive Committee (JBEC),  The American Chamber of Commerce in Japan Pharmaceuticals subcommittee, European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan)
PDF
PDF
February 14, 2012
PFSB/SD0214 No.9
Efforts to Raise Awareness of the Precautions for Anti-Influenza Drugs PDF
January 20, 2012
PFSB/ELD0120 No.1
PFSB/CND0120 No.1
Points for Consideration concerning the Use of Lysozyme Hydrochloride Preparations PDF
PDF
December 12, 2011
PFSB/ELD1212 No.1
PFSB/SD1212 No.1
PFSB/CND1212 No.2
Points for Consideration concerning the Use of Warfarin Potassium Preparations PDF
PDF
November 22, 2011
PFSB/SD1122 No.7
Efforts to Raise Awareness of the Precautions for Anti-Influenza Drugs PDF
PDF
July 29, 2011
PFSB/SD0729 No.1
Meeting to Exchange Opinions concerning Promotion of the use of the PMDA medi-navi (request)
(Appendix: Summary of the Meeting to Exchange Opinions concerning Promotion of the use of the Pharmaceutical and Medical Device Information E-mail Alert Service)
PDF
PDF
July 15, 2011
PFSB/SD0715 No.3
Provision of Drug Safety Information PDF
March 1, 2011
PFSB/SD0301 No.1
PFSB/SD0301 No.2
Efforts to Promote Proper Use of Gemtuzumab Ozogamicin (genetical recombination)
Reference: Report on investigation results regarding the safety of pharmaceutical products, etc.
Related information: Regulatory actions taken in the US related to Mylotarg for Injection 5mg (nonproprietary name: gemtuzumab ozogamicin) (June 22, 2011)
PDF
PDF
PDF
January 7, 2011
PFSB/SD0107 No.1
Change in Category Listing for OTC Drugs PDF
December 22, 2010
PFSB/GAD 1222 No.1
PFSB/SD1222 No.1
Precautions concerning Marketing of OTC Cold Medicines with Pediatric Use (Internal Use), Antitussive and Expectorant Drugs (Internal use), and Medicines for Rhinitis (request for circulation) PDF
October 26, 2010
PFSB/SD1026 No.3
Periodic Report on the Safety of Drugs and Quasi-drugs Containing DEET PDF
June 14, 2010
PFSB/ELD0614 No.10
Revision of Package Inserts concerning Continuous Use of Atomoxetine Hydrochloride Preparations in ADHD Patients from Childhood to Adulthood PDF
PDF
June 1, 2010
PFSB/GAD 0601 No.6
PFSB/SD0601 No.3
Points for Consideration regarding Marketing of OTC Antitussives and Expectorants (internal use) Containing Codeine Phosphate Hydrate and Dihydrocodeine Phosphate PDF
March 1, 2010
PFSB/ELD0301 No.1
PFSB/SD0301 No.5
PFSB/CND 0301 No.6
Points for Consideration concerning the Use of Distigmine Bromoide Preparations (internal use) PDF
PDF
January 13, 2010
PFSB/SD0113 No.1
Efforts to Raise Awareness of the Precautions of Peramivir Preparations and Request regarding the Precautions After the Start of Treatment for Influenza A (H1N1) PDF
January 13, 2010
PFSB/ELD0113 No.1
PFSB/SD0113 No.2
Post-marketing Safety Measures, etc. related to Peramivir Preparations PDF
January 13, 2010
PFSB/ELD0113 No.2
PFSB/SD0113 No.3
Request for Cooperation in Determining Total Usage Statistics for Peramivir Preparations PDF
November 30, 2009
Administrative Notice
Precautions After the Start of Influenza A (H1N1) Treatment
PDF
PDF
October 9, 2009
PFSB/SD1009 No.1
Safety Measures related to Influenza A (H1N1) Vaccines PDF
September 4, 2009
PFSB/SD0904 No.1
PFSB/SD0904 No.2
PFSB/SD0904 No.3
Safety Measures related to Anti-Influenza Drugs in connection with the Influenza A (H1N1) Epidemic PDF
September 4, 2009
PFSB/SD0904 No.4
PFSB/SD0904 No.5
PFSB/SD0904 No.6
Efforts to Raise Awareness of the Precautions for Anti-Influenza Drugs PDF
March 24, 2006
PFSB/SD No.0324006
Efforts to Optimize the Provision of Information concerning Generic Drugs PDF
October 16, 2008
PFSB/ELD No.0716001
Points for Consideration concerning the Use of Pirfenidone Preparations PDF
July 16, 2008
PFSB/ELD No.0716001
Points for Consideration concerning the Use of Sodium Risedronate Hydrate Preparations PDF
October 26, 2007
PFSB/GAD No.1026001
PFSB/ELD No.1026002
PFSB/SD No.1026001
PFSB/CND No.1026003
Points for Consideration concerning the Use of Methylphenidate Hydrochloride Preparations PDF

 

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

  • Contact us
  • Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

000046305
0
Notifications Related to Safety Measures (Drugs)
/english/safety/info-services/drugs/safety-measures/0001.html
en